文献速递妇科

辅助化疗与观察在I期卵巢透明细胞癌中的系统评价与荟萃分析

Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2020-01-21

该系统评价与荟萃分析纳入5073例I期卵巢透明细胞癌(OCCC)患者,比较辅助化疗与观察的疗效。汇总数据显示辅助化疗对总体人群的5年无病生存率和总生存率无显著影响,但亚组分析提示IC期患者接受辅助化疗与总生存改善相关。结论认为辅助化疗可保留用于IC期,而IA和IB期可安全省略。

要点

  • I期OCCC总体5年无病生存率83.7%,5年总生存率86.9%。
  • 总体人群中辅助化疗未显著改善5年无病生存(p=0.86)和总生存(p=0.53)。
  • IC期患者辅助化疗与总生存改善相关(OR=0.70,95%CI 0.52-0.93,p=0.01)。

核心结论

  • 辅助化疗可保留用于IC期OCCC患者,而IA和IB期可安全省略。
  • 由于纳入研究的固有偏倚,仍需进一步前瞻性证据。

研究设计与样本

  • 系统评价与荟萃分析,已在PROSPERO注册(ID: #129628),遵循PRIMA指南定义方案。
  • 研究总人群包括5073例女性。

主要发现

  • I期OCCC的5年无病生存率为83.7%,5年总生存率为86.9%。
  • 总体人群中辅助化疗对5年无病生存无显著影响(Z=0.18;p=0.86)。
  • 总体人群中辅助化疗对5年总生存无显著影响(Z=0.62;p=0.53)。
  • 在2264例IC期OCCC中,辅助化疗与总生存改善相关(OR: 0.70 (95%CI: 0.52 to 0.93);Z=2.44;p=0.01)。

关键数值与推荐

  • IC期OCCC辅助化疗与总生存改善相关:OR=0.70(95%CI 0.52-0.93),p=0.01。
  • 总体人群5年无病生存率83.7%,5年总生存率86.9%。

临床怎么用

  • 对于IA和IB期OCCC患者,可考虑省略辅助化疗。
  • 对于IC期OCCC患者,辅助化疗可能改善总生存,可考虑使用。

局限性

  • 纳入研究存在固有偏倚。
  • 需要进一步前瞻性证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of adjuvant chemotherapy in surgically staged stage I clear cell ovarian cancer (OCCC) is unclear. Here, we performed a systematic review and meta-analysis in order to evaluate the role of chemotherapy vs. observation in stage I OCCC. This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; ID: #129628). A protocol was defined prior to the search include the population criteria, description of interventions, comparisons, and the outcomes of interest, according to the PRIMA guidelines. Overall, the study population included 5073 women. Stage I OCCC experienced a 5-year disease-free survival and a 5-year overall survival of 83.7% and 86.9%, respectively. Pooled data suggested that in the overall population adjuvant chemotherapy did not impact on 5-year disease free survival (test for overall effect, Z = 0.18; p = 0.86) and 5-year overall survival (test for overall effect, Z = 0.62; p = 0.53). Focusing on 2264 stage IC OCCC we observed that adjuvant correlated with an improvement in overall survival (OR: 0.70 (95%CI: 0.52 to 0.93); Z = 2.44; p = 0.01). In conclusion our study underlines that adjuvant chemotherapy could be reserved for patients with stage IC OCCC; while in stage IA and IB it could be safely omitted. Owing to the inherent biases of the studies included in the meta-analysis further prospective evidences are needed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bogani G, Ditto A, Lopez S, et al. Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2020. PMID: 31980220. doi:10.1016/j.ygyno.2019.12.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。